



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/216038/2019

European Medicines Agency decision P/0139/2019

of 17 April 2019

on the acceptance of a modification of an agreed paediatric investigation plan for nonacog beta pegol (Refixia), (EMEA-000731-PIP01-09-M03) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us

Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

An agency of the European Union



European Medicines Agency decision

P/0139/2019

of 17 April 2019

on the acceptance of a modification of an agreed paediatric investigation plan for nonacog beta pegol (Refixia), (EMEA-000731-PIP01-09-M03) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/292/2010 issued on 22 December 2010, the decision P/0226/2013 issued on 23 September 2013 and the decision P/0329/2014 issued on 11 December 2014.

Having regard to the application submitted by Novo Nordisk A/S on 23 November 2018 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 1 March 2019, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for nonacog beta pegol (Refixia), powder and solvent for solution for injection, intravenous use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Novo Nordisk A/S, Novo Allé, 2880 - Bagsværd, Denmark.



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/873082/2018

London, 1 March 2019

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-000731-PIP01-09-M03

Scope of the application

Active substance(s):

Nonacog beta pegol

Invented name:

Refixia

Condition(s):

Treatment of hereditary factor IX deficiency

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Powder and solvent for solution for injection

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Novo Nordisk A/S

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Novo Nordisk A/S submitted to the European Medicines Agency on 23 November 2018 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision



P/292/2010 issued on 22 December 2010, the decision P/0226/2013 issued on 23 September 2013 and the decision P/0329/2014 issued on 11 December 2014.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 3 January 2019.

Scope of the modification

Some measures of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable.

2. Paediatric Investigation Plan

2.1. Condition

Treatment of hereditary factor IX deficiency

2.1.1. Indication(s) targeted by the PIP

Treatment and prophylaxis of bleeding in haemophilia B

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Powder for solution for injection, intravenous use

2.1.4. Measures

Area	Number of studies	Description
Quality-related studies	0	Study 1 Study deleted during procedure EMEA-000731-PIP01-09-M03
Non-clinical studies	0	Not applicable
Clinical studies	4	Study 2 Multi-centre, single-blind study to assess PK, safety and efficacy of on-demand and prophylactic treatment with N9-GP in adults and adolescents with haemophilia B Study 3 Non-randomised, open-label, multicentre, multinational, single-arm, non-controlled, efficacy and safety trial to assess the efficacy and safety of N9-GP during surgical procedures in patients with haemophilia B Study 4 Open-label, multicentre, uncontrolled, PK, safety and efficacy trial to assess the efficacy and safety of N9-GP in previously treated children less than 13 years of age with haemophilia B

		Study 5 Open-label, multicentre, uncontrolled, safety and efficacy trial in previously untreated patients with haemophilia B
Extrapolation, modelling and simulation studies	0	Not applicable
Other studies	0	Not applicable
Other measures	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By October 2020
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of Treatment of hereditary factor IX deficiency

Authorised indication(s):

- Treatment and prophylaxis of bleeding in patients 12 years and above with haemophilia B (congenital factor IX deficiency)

Authorised pharmaceutical form(s):

Powder and solvent for solution for injection

Authorised route(s) of administration:

Intravenous use